Glancy Binkow & Goldberg LLP, Representing Shareholders of Repros Therapeutics Inc., Announces There are 11 Days Remaining to Move for Appointment as Lead Plaintiff -- RPRX

• Press Release
• Source: Glancy Binkow & Goldberg LLP
• On 8:30 pm EDT, Friday September 25, 2009

LOS ANGELES, Sept. 25, 2009 (GLOBE NEWSWIRE) -- Glancy Binkow & Goldberg LLP announces that all persons or entities who purchased or otherwise acquired the common stock of Repros Therapeutics Inc. ("Repros" or the "Company") (Nasdaq:RPRX - News) between July 1, 2009 and August 3, 2009, inclusive (the "Class Period"), have only 11 days until the October 6, 2009, deadline to move the Court to serve as Lead Plaintiff in the securities fraud class action lawsuit. The case filed by Glancy Binkow & Goldberg LLP, Medina v. Repros Therapeutics Inc., et al., No. 09-cv-2594, has been assigned to the Honorable Kenneth M. Hoyt, United States District Judge for the Southern District of Texas.

Related Quotes

Symbol	Price	Change
RPRX	0.74	-0.05

{"s" : "rprx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

A copy of the Complaint is available from the court or from Glancy Binkow & Goldberg LLP. Please contact us by phone to discuss this action or to obtain a copy of the Complaint at (310) 201-9150 or Toll Free at (888) 773-9224, by email at info@glancylaw.com, or visit our website at http://www.glancylaw.com.

Repros focuses on the development of oral small-molecule drugs for the treatment of male and female reproductive disorders. The Company's lead drug, Proellex, is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis and as a pre-surgical treatment for anemia associated with excessive menstrual bleeding related to uterine fibroids. The Complaint charges the Company and certain of its executive officers with violations of the Securities Exchange Act of 1934, among other things, and further alleges that throughout the Class Period defendants knew or recklessly disregarded that their public statements concerning Repros' business and prospects were materially false and misleading. Specifically, plaintiff alleges that defendants knew or recklessly disregarded and failed to disclose that Proellex elevated liver enzymes to dangerous levels in certain patients participating in the drug's clinical trials,

The Private Securities Litigation Reform Act of 1995 ("PSLRA") requires the Court to appoint a "Lead Plaintiff" in this case. Any person or group who suffered a loss as a result of purchasing Repros common stock between July 1, 2009 and August 3, 2009, may ask the Court to be appointed as Lead Plaintiff, but must file a motion no later than the October 6, 2009 deadline.

Glancy Binkow & Goldberg LLP is a law firm with significant experience in prosecuting class actions, substantial expertise in actions involving corporate fraud, and is representing shareholders of Repros in this litigation.

If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, or Richard A. Maniskas, Esquire, of Glancy Binkow & Goldberg LLP, 1801 Avenue of the Stars, Suite 311, Los Angeles, California 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by e-mail to info@glancylaw.com.

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Lionel Z. Glancy 
Michael Goldberg 
Richard A. Maniskas
(310) 201-9150 
(888) 773-9224
info@glancylaw.com
www.glancylaw.com